FDA Wants More Data Before Approving Clinical Cell Culture Ltd.'s ReCell

Tissue engineering specialist Clinical Cell Culture's (ASX:CCE, C3) share price took a blow today, in the wake of a request by the US Food and Drug Administration (FDA) for more performance data before it can approve C3's ReCell for sale in the US.
MORE ON THIS TOPIC